Michael Holloway's most recent trade in Lixte Biotechnology Holdings Inc was a trade of 25,000 Options to Purchase Common Stock done . Disclosure was reported to the exchange on Aug. 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lixte Biotechnology Holdin... | Michael Holloway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2025 | 25,000 | 25,000 | - | - | Options to Purchase Common Stock |